Treatment
Lisocabtagene Maraleucel clinical trials
We’re tracking 12 recruiting studies that include Lisocabtagene Maraleucel, each written for real people, not researchers, below.
Recruiting studies
- NCT06794268Recruiting
Long-term health study for people with lymphoma treated with liso-cel
This study looks at patients with a type of lymphoma (follicular lymphoma) who have already received a CAR T-cell therapy called liso-cel. Researchers want to track their health over time and see how well the treatment works and how safe it is in routine medical care.
Milwaukee, WisconsinAges 18 years+ - NCT06788652Recruiting
Study of Liso-cel for mantle cell lymphoma after market approval
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
Milwaukee, WisconsinAges 18 years+ - NCT06788639Recruiting
Long-term study of Breyanzi for CLL/SLL in real-world care
This study looks at people with CLL or SLL who have already been treated with the CAR T-cell therapy lisocabtagene maraleucel (Breyanzi) in routine medical care. It collects information about how well the treatment works and how patients are doing over time, without giving any new treatment.
Milwaukee, WisconsinAges 18 years+ - NCT07194980RecruitingPhase 2
A two-drug approach for relapsed or refractory CLL/SLL
This study tests a combination of an oral targeted therapy (nemtabrutinib) followed by a personalized cell therapy (lisocabtagene maraleucel, also called liso-cel) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if this sequence can improve outcomes.
Seattle, WashingtonAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07316010RecruitingPhase 2
Liso-cel for lymphoma with minimal residual disease after first treatment
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
Houston, TexasAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT07052305RecruitingPhase 1
Testing NT-I7 after CAR T-cell therapy for large B-cell lymphoma
This trial tests whether a drug called NT-I7 (efineptakin alfa) can help people with large B-cell lymphoma who have already received a CAR T-cell treatment like Yescarta or Breyanzi. It aims to boost your immune system's recovery and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT07015242RecruitingPhase 2
Liso-cel as first treatment for primary CNS lymphoma
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
Aurora, ColoradoAges 18 years+ - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
Boston, MassachusettsAges 18 years+ - NCT06357754Recruiting
Testing tumor samples after BMS cell therapy and a second cancer
This trial offers testing of tumor samples for people who developed a new, different cancer after receiving a Bristol-Myers Squibb gene-modified cell therapy. The goal is to understand the genetics of that new cancer and see if it relates to the prior treatment.
Portland, OregonAges Any age
What Lisocabtagene Maraleucel is being studied for
Conditions with recruiting Lisocabtagene Maraleucel studies.
- Large B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Transformed Chronic Lymphocytic Leukemia
Common questions
- Are there clinical trials studying Lisocabtagene Maraleucel?
- Yes. Clin2 currently lists 12 recruiting studies that include Lisocabtagene Maraleucel, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Lisocabtagene Maraleucel trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Lisocabtagene Maraleucel an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Lisocabtagene Maraleucel or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.